FDA Says No to Changing the Label on Naproxen

The pain medicine naproxen, sold as Aleve, does not pose a lower risk of cardiovascular blood clots than other common pain medications such as Advil, Celebrex and ibuprofen, according to an expert medical panel convened by the Food and Drug Administration. The advisory committee reviewed FDA labeling rules that require pain medications known as non-steroidal anti-inflammatory drugs (NSAIDs) to carry a heart warning. It voted 16-9 that the available data don't support a conclusion that naproxen has a lower risk of cardiac problems compared with the other NSAIDs. Read the full story